The study, conducted by researchers at Pfizer Japan, IQVIA Solutions Japan, and Pfizer Inc., built a hybrid model combining a decision tree for the initial induction phase with a Markov framework for maintenance and all subsequent lines of therapy. Patients who failed their first advanced therapy were assumed to switch to an alternative agent, then to a basket of remaining drugs, and eventually to best supportive care if they continued to lose response. The simulated population mirrored Japanese trial participants newly starting advanced therapy, with a mean age of 42.4 years and a mean body weight of 59.7 kilograms. Efficacy and safety inputs came from a Bayesian network meta-analysis covering ten advanced therapies, supplemented with Japan-specific costs drawn from a nationwide claims database and adjusted to 2025 price levels.

The economics were evaluated from the perspective of the Japanese payer, with both costs and quality-adjusted life years discounted at an annual rate of 2.0 percent, in line with national health technology assessment guidelines. The willingness-to-pay threshold was set at JPY 7,500,000 per QALY, roughly USD 49,547, the benchmark used in Japan’s system for designated intractable diseases, a category to which ulcerative colitis belongs. Only serious infections were modelled as adverse events, a choice consistent with previous economic evaluations in this therapeutic area, because they drive the greatest costs and quality-of-life impairment while safety profiles across the drug classes remain broadly similar.

The central result was striking in its clarity. Among all 79 sequences evaluated, starting with etrasimod and following with upadacitinib produced the greatest lifetime health benefit, a total of 17.801 quality-adjusted life years. Four strategies anchored the efficiency frontier, the curve tracing the most efficient options at each cost level: infliximab followed by ustekinumab, infliximab followed by etrasimod, infliximab followed by upadacitinib, and etrasimod followed by upadacitinib. Each successive step along the frontier bought more health at an incremental cost-effectiveness ratio comfortably below the Japanese threshold, culminating in etrasimod followed by upadacitinib at JPY 6,684,442 per QALY, which remained cost-effective and delivered the most value overall.

The mechanistic logic behind the winning sequence is instructive. The network meta-analysis showed that upadacitinib, an oral JAK inhibitor, achieved the highest remission and response rates among patients who had already been exposed to advanced therapy, making it a particularly powerful second-line option. Etrasimod, which traps lymphocytes in lymph nodes by modulating the S1P receptor on their surface and thereby blunts intestinal inflammation while preserving systemic immune surveillance, showed favorable efficacy and safety across multiple endpoints in treatment-naïve patients. Pairing the two oral agents in that order therefore maximized cumulative quality-adjusted survival, and etrasimod outperformed ozanimod, its identically priced oral counterpart, on maintenance response, remission, and serious infection rates in the comparative evidence underpinning the model.

Sensitivity analyses revealed where the conclusion could shift. When infliximab and adalimumab biosimilars were introduced into the model, the picture changed materially. Because biosimilar infliximab costs JPY 13,860 per 100-milligram vial compared with JPY 35,981 for the originator, a first-line biosimilar infliximab sequence followed by upadacitinib became the most cost-effective strategy, pushing the etrasimod-upadacitinib combination above the threshold. Yet the authors caution that real-world biosimilar uptake in Japanese ulcerative colitis remains around 20 percent, and a survey found that 85 percent of Japanese inflammatory bowel disease patients were unaware biosimilars even existed. Under Japan’s high-cost medical expense benefit program, out-of-pocket costs are so constrained that patients have little financial incentive to switch.

Other scenario analyses tested alternative assumptions about disease progression and treatment intensity. Allowing dose escalation of tofacitinib, upadacitinib, and ustekinumab during maintenance left etrasimod followed by upadacitinib as the most cost-effective sequence, though with a narrower margin. Assuming patients never transitioned from later-line therapy to best supportive care shifted the optimal sequence to etrasimod followed by ustekinumab. Applying higher colectomy rates, informed by Japanese national database studies, moved infliximab followed by upadacitinib to the top. The fragility of the base-case result was further underlined by the one-way sensitivity analysis, in which placebo-arm maintenance parameters and infliximab’s relative efficacy had the largest influence on the incremental net monetary benefit.

The study carries important caveats that temper any temptation to treat its ranking as clinical gospel. Efficacy estimates derive from a network meta-analysis of trials published through November 2022, and such analyses for ulcerative colitis are known to suffer from heterogeneity in prior biologic exposure, baseline disease activity, and outcome definitions. Real-world evidence, which now exists for several of the agents, was excluded because of incomparability across studies. Serious infections were the only adverse event modelled, leaving unquantified risks such as major cardiovascular events, venous thromboembolism, herpes zoster, and malignancy, factors that matter greatly in real treatment choices. Utility values came largely from non-Japanese populations, and the transition rate from late-line therapy to best supportive care was borrowed from a United States claims database.

There is also the question of who conducted the analysis. All clinical authors are Pfizer employees or contractors funded by Pfizer Japan, and the company financed the research and publication. The acknowledged conflicts do not invalidate the mathematics, but they do mean the framing of etrasimod, a Pfizer drug, as the preferred starting point deserves independent scrutiny, particularly given how sensitive the results were to pricing assumptions around cheaper biosimilars.

For clinicians and policymakers, the study’s value lies less in crowning a single winner than in demonstrating that sequencing choices carry quantifiable economic and health consequences over a lifetime of disease. The authors themselves stress that the findings should complement, not dictate, clinical judgement, alongside patient age, comorbidities, pregnancy plans, and personal preference. As Japan’s ulcerative colitis population grows, having expanded roughly 1.4-fold over eight years, and as real-world data accumulate on the newer oral agents, future updates of this model will be needed to confirm whether the etrasimod-then-upadacitinib pathway truly delivers the best value in everyday practice rather than in simulation.

Subject of Research: Cost-effectiveness modeling of advanced therapy sequences for moderately to severely active ulcerative colitis in Japan

Article Title: Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan

Article References: Kamei, K., Enami, M., Matsuda, H., Yamagami, K., Dai, Y., Hoshi, M., Law, E. H., & Yuasa, A. (2026). Comparative Cost-Effectiveness of Advanced Treatment Sequences for Moderately to Severely Active Ulcerative Colitis in Japan. Advances in Therapy. https://doi.org/10.1007/s12325-026-03757-3

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03757-3

Keywords: ulcerative colitis, cost-effectiveness, etrasimod, upadacitinib, infliximab, S1P receptor modulators, JAK inhibitors, network meta-analysis, QALY, Japan, biosimilars, treatment sequencing

The research, led by a team working at the interface of mechanobiology and skin biology, addresses a long-standing puzzle in tissue physiology. Skin must maintain structural integrity while simultaneously accommodating growth, wound repair, and chronic mechanical stress such as repeated friction or tension. How a tissue senses these forces and translates them into molecular remodeling programs has been studied extensively at the level of individual mechanosensitive channels and cytoskeletal adapters. Far less is understood about which specialized cell subpopulations act as the conductors of this whole-tissue response.

Fibroblasts, the connective tissue workhorses of the dermis, have long been treated as a relatively uniform population of cells that deposit collagen and other extracellular matrix components. Over the past decade, single-cell technologies have shattered that view, revealing that fibroblasts exist in a spectrum of functionally distinct states, each occupying specific anatomical niches and performing specialized duties. Among the markers that have drawn intense interest is LGR5, a receptor best characterized as a Wnt target gene and a hallmark of adult stem cells in the intestine, hair follicle, and several other organs. Its appearance on a subset of dermal fibroblasts hinted that these cells might occupy a privileged regulatory position within skin.

The new findings place those LGR5-positive fibroblasts at the center of what the authors describe as skin mechanoadaptation, the process by which the tissue adjusts its architecture and mechanical properties in response to physical forces. According to the study, when skin is subjected to mechanical loading, these cells do not merely respond passively. Instead, they act as orchestrators, integrating mechanical cues and broadcasting instructions to surrounding cells through inflammatory and remodeling pathways, with JAK1 serving as a critical signaling node in that communication.

JAK1, or Janus kinase 1, is a cytoplasmic tyrosine kinase that relays signals from a family of cytokine receptors into the cell interior, most famously activating the STAT transcription factors that drive genes involved in immunity, cell growth, and tissue repair. Drugs targeting the JAK family have transformed the treatment of inflammatory diseases and certain cancers, making JAK1 one of the most pharmacologically scrutinized kinases in modern medicine. The revelation that JAK1 functions as a mechanotransductive regulator within a specialized fibroblast subset adds an entirely new dimension to its biological portfolio, and suggests that mechanical stress and inflammatory signaling in skin are more deeply intertwined than previously appreciated.

The implications extend well beyond basic cell biology. Excessive or aberrant mechanical stress is implicated in a range of cutaneous pathologies, from hypertrophic scarring and fibrosis to pressure ulcers and the progressive stiffening of aged skin. Conversely, insufficient mechanoadaptation can compromise wound closure and tissue resilience. If LGR5-positive fibroblasts genuinely coordinate the tissue-wide response to force through JAK1 signaling, then therapeutic strategies aimed at this specific cellular niche could, in principle, recalibrate how skin responds to stress, promoting healthy remodeling while dampening pathological fibrosis.

To reach these conclusions, the research team combined state-of-the-art lineage tracing with mechanical perturbation of skin tissue. Genetic fate-mapping approaches, in which cells expressing LGR5 and their descendants are permanently labeled, allowed the investigators to follow the behavior of this fibroblast subset under basal conditions and in response to mechanical challenge. Complementing the lineage studies, transcriptomic profiling revealed the molecular identity of the mechanoadaptive program, pinpointing JAK1-dependent signaling as a central feature of how these cells translate physical input into changes in gene expression and, ultimately, tissue architecture.

When the investigators disrupted JAK1 function in the context of mechanical loading, the coordinated adaptive response faltered, supporting the model that LGR5-positive fibroblasts require this kinase to fulfill their regulatory role. The finding reframes mechanotransduction not as a cell-autonomous affair confined to force-sensing proteins at the membrane, but as an intercellular program in which a small population of specialized stromal cells interprets mechanical context and modulates the behavior of the tissue as a collective. In this view, fibroblasts act less like passive scaffolding cells and more like mechanical stethoscopes and loudspeakers rolled into one, listening to the physical state of the skin and broadcasting chemical instructions accordingly.

For the broader field of mechanobiology, the study contributes to a growing recognition that stromal cells are active participants in how organs sense and respond to their physical environment. Similar sentinel populations have been described in other tissues, where specialized fibroblasts guide immune responses, organize repair zones after injury, and maintain niche architecture. The identification of an LGR5-marked, JAK1-modulating subset in skin strengthens the argument that tissue-level mechanoadaptation depends on a division of labor among fibroblast states, and that understanding this division of labor is essential for regenerative medicine.

Translational questions now loom large. Because JAK inhibitors are already in widespread clinical use, the findings raise the possibility that existing drugs, or more selective derivatives, could be repurposed to modulate skin mechanoadaptation in contexts ranging from scar prevention to anti-fibrotic therapy. At the same time, the study serves as a caution: wholesale blockade of JAK signaling in skin could interfere with beneficial adaptive remodeling, and the challenge ahead lies in achieving the right specificity, both at the level of the kinase and at the level of the cell type. As researchers work toward that precision, the humble dermal fibroblast, once dismissed as connective tissue filler, has firmly claimed its place as a master regulator of how skin meets the mechanical world.

The choice of LGR5 as a marker reflects a broader shift in how biologists identify functionally important cell types. Because LGR5 marks actively cycling stem cells in rapidly renewing epithelia, its expression in the dermis initially suggested that these fibroblasts might retain an unusual developmental plasticity. Fate-mapping studies in other organs have shown that LGR5-positive populations can generate diverse progeny, and the present work extends that logic to the stromal compartment, where a marked subset appears to exert influence less through self-renewal than through signaling authority over its neighbors.

The dermal microenvironment in which these cells reside is itself worth considering. The dermis is organized into papillary and reticular layers with distinct collagen densities, vascular supplies, and resident cell compositions, and fibroblasts occupying these layers differ in gene expression and in the mechanical properties of the matrix they produce. Mechanical forces impinging on the skin surface are transmitted through this layered architecture in complex ways, so a subset positioned at a particular depth or niche may be uniquely situated to sense deformation and relay that information to immune cells, endothelial cells, and epithelial stem cells above.

The connection between mechanical loading and cytokine signaling illuminated here also fits with accumulating evidence that physical forces can modulate inflammatory pathways independently of infection or tissue damage. Stretch, compression, and fluid shear have all been shown to alter cytokine production in cultured cells, and the JAK-STAT pathway is a common downstream convergence point for such signals. Placing JAK1 within a mechanotransductive circuit in intact skin provides an in vivo anchor for observations that had largely been made in simplified culture systems, where the multicellular architecture of real tissue is absent.

From a clinical standpoint, the findings intersect with a persistent therapeutic dilemma in dermatology. Antifibrotic interventions aim to reduce excessive collagen deposition, yet collagen synthesis is also essential for normal wound healing, and blunt suppression of matrix production can impair closure and strength of repaired skin. A regulatory node that acts specifically during mechanical adaptation offers a potential middle path: modulating it might allow clinicians to distinguish pathological responses to chronic aberrant loading from the beneficial remodeling that follows injury or surgical repair.

The study also speaks to the biology of skin aging, in which the dermis loses elasticity and becomes progressively stiffer, in part through changes in fibroblast number, phenotype, and extracellular matrix turnover. Whether the LGR5-positive mechanoadaptive population declines, shifts state, or becomes functionally silenced with age is an obvious next question, and one that could connect mechanoadaptation to the well-documented observation that aged skin heals more slowly and scars differently than young skin.

Methodologically, the work illustrates the value of combining lineage tracing with controlled mechanical perturbation, an approach that is becoming more common as researchers recognize that static snapshots of gene expression cannot capture how cells respond dynamically to force. Transcriptomic profiling under defined loading conditions, paired with genetic disruption of candidate signaling mediators, provides a framework that other groups studying lung, gut, or cardiovascular mechanobiology may adapt, since stromal sentinel populations are increasingly suspected in those organs as well.

Important caveats remain before the model can be considered complete. Mouse studies with genetic fate mapping do not automatically translate to human skin, whose dermal architecture and fibroblast heterogeneity differ in notable ways, and the precise identity of the upstream mechanical sensor in these cells has yet to be defined. Whether JAK1 modulation acts directly on mechanosensitive transcription or indirectly through cytokines released by neighboring cells will require careful dissection. Nonetheless, the demonstration that a defined fibroblast subset can govern tissue-wide mechanical adaptation marks a substantive step toward a cell-type-resolved understanding of how skin endures the physical demands of daily life.

Subject of Research: The role of LGR5-positive fibroblasts in coordinating skin mechanoadaptation via JAK1 signaling

Article Title: LGR5-positive fibroblasts orchestrate skin mechanoadaptation through JAK1 modulation

Article References: Fu, Q., Cheng, X., Chen, N., Sun, Y., Xu, L., Cheng, Y., Wang, C., Li, Y., Yu, T., Yan, Y., Zhang, W., Bu, Y., Lei, L., Chen, Y., Li, Z., Zhu, P., Wang, C., Zhang, L., Liu, C., & Li, Q. (2026). LGR5-positive fibroblasts orchestrate skin mechanoadaptation through JAK1 modulation. Nature Communications. https://doi.org/10.1038/s41467-026-77113-y

Image Credits: AI Generated

DOI: 10.1038/s41467-026-77113-y

Keywords: LGR5, fibroblasts, skin, mechanoadaptation, JAK1, mechanotransduction, Nature Communications, dermis, tissue remodeling, JAK inhibitors, single-cell analysis, skin biology